Compare
Twist Bioscience Corp vs Krystal Biotech, Inc. vs Immunocore Holdings plc vs Tarsus Pharmaceuticals, Inc.
| Latest fiscal year | Twist Bioscience Corp TWST | Krystal Biotech, Inc. KRYS | Immunocore Holdings plc IMCR | Tarsus Pharmaceuticals, Inc. TARS |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $376.57M | $389.13M | $400.02M | $451.36M |
| Revenue growth (YoY) | +20.3% | +33.9% | +29.0% | +146.7% |
| Gross margin | 50.7% (computed) | n/a | n/a | n/a |
| Operating margin | -36.2% | 41.5% | -11.3% | -15.7% |
| Net margin | -20.6% | 52.6% | -8.9% | -14.7% |
| Net income | -$77.67M | $204.83M | -$35.51M | -$66.42M |
| EPS (Diluted) | -$1.30 | $6.84 | -$0.71 | -$1.59 |
| Operating cash flow | -$47.63M | $200.87M | -$10.71M | -$12.45M |
| Free cash flow | -$75.63M | $188.91M | -$15.05M | -$22.31M |
| Cash & equivalents | $183.05M | $496.30M | $467.71M | $183.64M |
| Total assets | $641.86M | $1.33B | $1.07B | $562.16M |
| Total liabilities | $168.90M | $114.23M | $686.24M | $218.73M |
| Shareholders' equity | $472.96M | $1.22B | $381.03M | $343.43M |
| Return on year-end equity | -16.4% | 16.8% | -9.3% | -19.3% |
| Shares outstanding | 60.63M | 29.19M | 50.69M | 42.55M |
Revenue, most recent five fiscal years
| Fiscal year | Twist Bioscience Corp | Krystal Biotech, Inc. | Immunocore Holdings plc | Tarsus Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $376.57M Ended 2025-09-30 | $389.13M Ended 2025-12-31 | $400.02M Ended 2025-12-31 | $451.36M Ended 2025-12-31 |
| 1 year earlier | $312.97M Ended 2024-09-30 | $290.51M Ended 2024-12-31 | $310.20M Ended 2024-12-31 | $182.95M Ended 2024-12-31 |
| 2 years earlier | $245.11M Ended 2023-09-30 | $50.70M Ended 2023-12-31 | $249.43M Ended 2023-12-31 | $17.45M Ended 2023-12-31 |
| 3 years earlier | $203.56M Ended 2022-09-30 | $0 Ended 2022-12-31 | $174.36M Ended 2022-12-31 | $25.82M Ended 2022-12-31 |
| 4 years earlier | $132.33M Ended 2021-09-30 | $0 Ended 2021-12-31 | $36.48M Ended 2021-12-31 | $57.03M Ended 2021-12-31 |